Serum TWEAK Levels and Treatment Outcomes in Psoriasis and Psoriatic Arthritis

Overview

This prospective study assessed serum TWEAK levels in patients with psoriasis and psoriatic arthritis (PsA) treated with adalimumab and methotrexate, respectively. Significant differences in TWEAK levels were observed between patient groups and controls, with correlations to clinical severity indices (PASI and DAPSA) and treatment response over 24 weeks.

Background

Psoriasis is a chronic immune-mediated skin disease affecting 2–3% of the population, with up to 40% developing psoriatic arthritis, an inflammatory joint disease. Both conditions involve systemic inflammation and cytokine dysregulation, including the TNF-related weak inducer of apoptosis (TWEAK), which promotes inflammation and tissue remodeling. Biologic therapies like adalimumab and conventional DMARDs such as methotrexate are standard treatments, but their effects on TWEAK modulation remain underexplored. This study investigates serum TWEAK as a biomarker for disease activity and treatment response in psoriatic disease.

Data Highlights

Key Findings

• Serum TWEAK levels were significantly higher in psoriasis and PsA patients compared to healthy controls at baseline.
• Adalimumab treatment in psoriasis patients led to a significant reduction in serum TWEAK levels after 24 weeks.
• Methotrexate treatment in PsA patients also reduced TWEAK levels, though the study reflects real-world therapeutic standards rather than randomized allocation.
• Changes in TWEAK levels correlated with improvements in PASI scores for psoriasis and DAPSA scores for PsA, indicating TWEAK as a potential biomarker for disease activity and treatment response.
• The study included 40 controls, 30 psoriasis patients, and 30 PsA patients, ensuring adequate power to detect differences in TWEAK levels.

Clinical Implications

Monitoring serum TWEAK levels may provide a useful biomarker for assessing disease activity and therapeutic response in patients with psoriasis and psoriatic arthritis. Both adalimumab and methotrexate treatments are associated with reductions in TWEAK, paralleling clinical improvement, supporting their role in modulating inflammatory pathways involving TWEAK. Incorporating TWEAK measurement could enhance personalized treatment strategies.

Conclusion

Serum TWEAK is elevated in psoriatic disease and decreases with effective treatment, correlating with clinical improvement. These findings support TWEAK as a promising biomarker for monitoring disease activity and response to therapy in psoriasis and PsA.

References

1. Psoriasis Prevalence and Impact, Source 1
2. Psoriatic Arthritis Characteristics, Source 2
3. Role of TWEAK in Inflammation, Sources 3,4,5,10
4. Therapeutic Use of Adalimumab and Methotrexate, Sources 6,7
5. PASI and DAPSA Scoring Methods, Sources 20,21